EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

Published:2019-08 Issue:8 Volume:30 Page:1311-1320
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Hastings K.^ORCID,Yu H.A.,Wei W.,Sanchez-Vega F.,DeVeaux M.,Choi J.,Rizvi H.,Lisberg A.,Truini A.,Lydon C.A.,Liu Z.,Henick B.S.,Wurtz A.,Cai G.,Plodkowski A.J.,Long N.M.,Halpenny D.F.,Killam J.,Oliva I.,Schultz N.,Riely G.J.,Arcila M.E.,Ladanyi M.,Zelterman D.,Herbst R.S.,Goldberg S.B.,Awad M.M.,Garon E.B.,Gettinger S.,Hellmann M.D.,Politi K.

Funder

National Institutes of Health/National Cancer Institute

NIH

NCI

Italian Association for Cancer Research

Department of Defense Lung Cancer Research Program Idea

Diane and David Heller Foundation

Ginny and Kenneth Grunley Fund for Lung Cancer Research

Brown Performance Group Fund for Innovation in Cancer Informatics

Druckenmiller Center for Lung Cancer Research

Damon Runyon Clinical Investigator

Damon Runyon Cancer Research Foundation

Parker Institute for Cancer Immunotherapy

Yale Cancer Center

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz141/28863126/mdz141.pdf

Reference40 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci U S A,2004

4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

Cited by 262 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group;Cancers;2024-09-09

2. Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer;CLIN LUNG CANCER;2024

3. Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer;Clinical Lung Cancer;2024-09

4. Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter?;Journal of Clinical Oncology;2024-08-26

5. Combination Therapy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel for Metastatic Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Resistance and EGFR Mutations;Cureus;2024-08-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3